Pharmacotherapies for glaucoma

Current Molecular Medicine

Volumn 10, Issue 9, 2010, Pages 824-840

  Toris, C B ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Aqueous humor dynamics; Carbonic anhydrase inhibitors; Cholinergic agents; Glaucoma; Parasympathomimetics; Prostaglandins; Sympathomimetics

Indexed keywords

3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ACETAZOLAMIDE; ADRENALIN; ADRENERGIC RECEPTOR STIMULATING AGENT; AL 34662; APRACLONIDINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BIMATOPROST; BRIMONIDINE; BRIMONIDINE PLUS TIMOLOL; BRINZOLAMIDE; BRINZOLAMIDE PLUS TIMOLOL; CARBACHOL; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; CHOLINERGIC RECEPTOR AFFECTING AGENT; DICLOFENAMIDE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; GLYCEROL; ISOSORBIDE; LATANOPROST; LATANOPROST PLUS TIMOLOL; LEVOBUNOLOL; METHAZOLAMIDE; METIPRANOLOL; PHYSOSTIGMINE; PILOCARPINE; PROSTAGLANDIN DERIVATIVE; SDZ PSD 958; TAFLUPROST; TIMOLOL; TIMOLOL PLUS TRAVOPROST; TRAVOPROST; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNOPROSTONE ISOPROPYL ESTER;

ANTERIOR EYE CHAMBER; AQUEOUS HUMOR; ARTICLE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; NONHUMAN; OPTIC NERVE INJURY; RETINA GANGLION CELL; SCLERA; TRABECULAR MESHWORK; UVEA; VISUAL IMPAIRMENT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; AQUEOUS HUMOR; CARBONIC ANHYDRASE INHIBITORS; GLAUCOMA; HUMANS;

EID: 78651313737     PISSN: 15665240     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652410793937778     Document Type: Article

References (215)

1. Sugrue MF. New approaches to antiglaucoma therapy. JMed Chem 1997; 40: 2793-809.
2. Kotecha A, Lim S, Garway-Heath D. In: Glaucoma, medicaldiagnosis & therapy, Shaarawy TM, Sherwood MB, Hitchings RG, Crowston JG, Eds. Saunders Elsevier Limited 2009; Vol.1: pp. 103-13.
3. Civan MM, Macknight ADC. The ins and outs of aqueoushumour secretion. Exp Eye Res 2004; 78: 625-31.
4. --antiporters of bovine pigmented ciliary epithelial cells. Pflugers Arch 2000; 440: 667-78.
5. Stamer WD, Baetz NW, Yool AJ. In: The eye's aqueoushumor, 2nd ed. Civan MM, Ed. San Diego: Elsevier, Inc 2008; Vol. 62: pp. 47-70.
6. Bill A. Blood circulation and fluid dynamics in the eye. Physiol Rev 1975; 55: 383-417.
7. Bito LZ, Wallenstein MC. Transport of prostaglandins acrossthe blood-brain and blood-aqueous barriers and thephysiological significance of these absorptive transportprocesses. Exp Eye Res 1977; 25: 229-43.
8. Reiss GR, Lee DA, Topper JE, Brubaker RF. Aqueoushumor flow during sleep. Invest Ophthalmol Vis Sci 1984; 25: 776-8.
9. Brubaker RF. Flow of aqueous humor in humans. Invest Ophthalmol Vis Sci 1991; 32: 3145-66.
10. Brubaker RF. In: The eye's aqueous humor. From secretionto glaucoma; Civan MM, Ed. San Diego: Academic Press 1998; Vol. 45: pp. 233-84.
11. Wang Y-L, Hayashi M, Yablonski ME, Toris CB. Effects ofmultiple dosing of epinephrine on aqueous humor dynamicsin human eyes. J Ocul Pharmacol Ther 2002; 18: 53-63.
12. Maus TL, Young WF, Jr., Brubaker RF. Aqueous flow inhumans after adrenalectomy. Invest Ophthalmol Vis Sci 1994; 35: 3325-31.
13. Wentworth WO, Brubaker RF. Aqueous humor dynamics in aseries of patients with third neuron Horner's syndrome. Am JOphthalmol 1981; 92: 407-15.
14. Jacob E, Fitz Simon JS, Brubaker RF. Combinedcorticosteroid and catecholamine stimulation of aqueoushumor flow. Ophthalmology 1996; 103: 1303-8.
15. Viggiano SR, Koskela TK, Klee GG, Samples JR, Arnce R, Brubaker RF. The effect of melatonin on aqueous humor flowin humans during the day. Ophthalmology 1994; 101: 326-31.
16. Ethier CR. The inner wall of Schlemm's canal. Exp Eye Res 2002; 74: 161-72.
17. Johnson M. What controls aqueous humour outflowresistance? Exp Eye Res 2006; 82: 545-57.
18. Gabelt BT, Kaufman PL. Changes in aqueous humordynamics with age and glaucoma. Prog Retin Eye Res 2005; 24: 612-37.
19. Read AT, Chan DW-H, Ethier CR. Actin structure in theoutflow tract of normal and glaucomatous eyes. Exp Eye Res 2007; 84: 214-26.
20. Sihota R, Lakshmaiah NC, Walia KB, Sharma S, Pailoor J, Agarwal HC. The trabecular meshwork in acute and chronicangle closure glaucoma. Indian J Ophthalmol 2001; 49: 255-9.
21. Joseph J, Grierson I. In: Pathobiology of ocular disease; adynamic approach. Garner A, Klintworth GK, Eds. New York:M. Dekker 1994; pp. 433-68.
22. Van Buskirk EM. The canine eye: lens depression andaqueous outflow. Invest Ophthalmol Vis Sci 1980; 19: 789-92.
23. Soto D, Comes N, Ferrer E, et al. Modulation of aqueoushumor outflow by ionic mechanisms involved in trabecularmeshwork cell volume regulation. Invest Ophthalmol Vis Sci 2004; 45: 3650-61.
24. Stjernschantz J, Selén G, Ocklind A, Resul B. In: Uveoscleraloutflow. Biology and clinical aspects; Alm A, Weinreb RN, Eds. London, UK: Mosby International Limited 1998; pp. 57-72.
25. Toris CB, Yablonski ME, Wang Y-L, Camras CB. Aqueoushumor dynamics in the aging human eye. Am J Ophthalmol 1999; 127: 407-12.
26. Toris CB, Koepsell SA, Yablonski ME, Camras CB. Aqueoushumor dynamics in ocular hypertensive patients. J Glaucoma 2002; 11: 253-8.
27. Grant WM. Clinical measurements of aqueous outflow. AMAArch Ophthalmol 1951; 46: 113-31.
28. Becker B. The decline in aqueous secretion and outflowfacility with age. Am J Ophthalmol 1958; 46: 731-6.
29. Gaasterland D, Kupfer C, Milton R, Ross K, McCain L, Mac Lellan H. Studies of aqueous humour dynamics in man. VI. Effect of age upon parameters of intraocular pressure innormal human eyes. Exp Eye Res 1978; 26: 651-6.
30. Sit AJ, Nau CB, McLaren JW, Johnson DH, Hodge D. Circadian variation of aqueous dynamics in young healthyadults. Invest Ophthalmol Vis Sci 2008; 49: 1473-9.
31. Johnson TV, Fan S, Camras CB, Toris CB. Aqueous humordynamics in exfoliation syndrome. Arch Ophthalmol 2008; 126: 914-20.
32. Camras CB, Haecker NR, Zhan G, Toris CB. Aqueous humordynamics in patients with pigment dispersion syndrome. Invest Ophthalmol Vis Sci 2003; 44: 2207.
33. Becker B. Tonography in the diagnosis of simple (openangle) glaucoma. Trans Am Acad Ophthalmol Otolaryngol 1961; 65: 156-62.
34. Zeimer RC. In: The glaucomas. Ritch R, Shields MB, Krupin T, Eds. St. Louis: The C. V. Mosby Company 1989; pp. 249-55.
35. Zeimer RC, Gieser DK, Wilensky JT, Noth JM, Mori MM, Odunukwe EE. A practical venomanometer. Measurement ofepiscleral venous pressure and assessment of the normalrange. Arch Ophthalmol 1983; 101: 1447-9.
36. Blondeau P, Tétrault JP, Papamarkakis C. Diurnal variationof episcleral venous pressure in healthy patients: a pilotstudy. J Glaucoma 2001; 10: 18-24.
37. Moses RA, Grodzki WJ, Jr., Carras PL. Pseudofacility. Where did it go? Arch Ophthalmol 1985; 103: 1653-5.
38. Sultan M, Blondeau P. Episcleral venous pressure inyounger and older subjects in the sitting and supinepositions. J Glaucoma 2003; 12: 370-3.
39. Yablonski ME, Gallin P, Shapiro D. Effect of oxygen onaqueous humor dynamics in rabbits. Invest Ophthalmol Vis Sci 1985; 26: 1781-4.
40. Ortiz GJ, Cook DJ, Yablonski ME, Masonson H, Harmon G. Effect of cold air on aqueous humor dynamics in humans. Invest Ophthalmol Vis Sci 1988; 29: 138-40.
41. Toris CB, Tafoya ME, Camras CB, Yablonski ME. Effects ofapraclonidine on aqueous humor dynamics in human eyes. Ophthalmology 1995; 102: 456-61.
42. Zamora DO, Kiel JW. Topical proparacaine and episcleralvenous pressure in the rabbit. Invest Ophthalmol Vis Sci 2009; 50: 2949-52.
43. Bill A. Conventional and uveo-scleral drainage of aqueoushumour in the cynomolgus monkey (Macaca irus) at normaland high intraocular pressures. Exp Eye Res 1966; 5: 45-54.
44. Toris CB, Pederson JE. Effect of intraocular pressure onuveoscleral outflow following cyclodialysis in the monkeyeye. Invest Ophthalmol Vis Sci 1985; 26: 1745-9.
45. Townsend DJ, Brubaker RF. Immediate effect of epinephrineon aqueous formation in the normal human eye as measuredby fluorophotometry. Invest Ophthalmol Vis Sci 1980; 19: 256-66.
46. Mishima HK, Kiuchi Y, Takamatsu M, Rácz P, Bito LZ. Circadian intraocular pressure management with latanoprost:diurnal and nocturnal intraocular pressure reduction andincreased uveoscleral outflow. Surv Ophthalmol 1997; 41:S139-S144.
47. Becker B. Decrease in intraocular pressure in man by acarbonic anhydrase inhibitor, diamox. A preliminary report. Am J Ophthalmol 1954; 37: 13-5.
48. Breinin GM, Gortz H. Carbonic anhydrase inhibitoracetazolamide (Diamox): a new approach to the therapy ofglaucoma. AMA Arch Ophthalmol 1954; 52: 333-48.
49. Grant WM, Trotter RR. Diamox (acetazolamide) in treatmentof glaucoma. AMA Arch Ophthalmol 1954; 51: 735-9.
50. Skorobohach BJ, Ward DA, Hendrix DVH. Effects of oraladministration of methazolamide on intraocular pressure andaqueous humor flow rate in clinically normal dogs. Am J Vet Res 2003; 64: 183-7.
51. Brechue WF, Maren TH. A comparison between the effect oftopical and systemic carbonic anhydrase inhibitors onaqueous humor secretion. Exp Eye Res 1993; 57: 67-78.
52. Vogh BP, Godman DR, Maren TH. Measurement of aqueoushumor flow following scleral injection of sulfacetamide asmarker: effect of methazolamide, timolol, and pilocarpine. JOcul Pharmacol 1989; 5: 293-302.
53. Bar-Ilan A, Pessah NI, Maren TH. The effects of carbonicanhydrase inhibitors on aqueous humor chemistry anddynamics. Invest Ophthalmol Vis Sci 1984; 25: 1198-205.
54. Stein A, Pinke R, Krupin T, et al. The effect of topicallyadministered carbonic anhydrase inhibitors on aqueoushumor dynamics in rabbits. Am J Ophthalmol 1983; 95: 222-8.
55. Kalina PH, Shetlar DJ, Lewis RA, Kullerstrand LJ, Brubaker RF. 6-amino-2-benzothiazole-sulfonamide. The effect of atopical carbonic anhydrase inhibitor on aqueous humorformation in the normal human eye. Ophthalmology 1988; 95: 772-7.
56. Supuran CT, Scozzafava A, Casini A. Carbonic anhydraseinhibitors. Med Res Rev 2003; 23: 146-89.
57. Mincione F, Scozzafava A, Supuran CT. The development oftopically acting carbonic anhydrase inhibitors asantiglaucoma agents. Curr Pharm Des 2008; 14: 649-54.
58. Civan MM. In: The eye's aqueous humor. 2nd ed. Civan MM, Ed. San Diego: Elsevier, Inc 2008; Vol. 62: pp. 1-45.
59. Shahidullah M, To CH, Pelis RM, Delamere NA. Studies onbicarbonate transporters and carbonic anhydrase in porcinenonpigmented ciliary epithelium. Invest Ophthalmol Vis Sci 2009; 50: 1791-800.
60. Maren TH, Haywood JR, Chapman SK, Zimmerman TJ. Thepharmacology of methazolamide in relation to the treatmentof glaucoma. Invest Ophthalmol Vis Sci 1977; 16: 730-42.
61. Phillips CI, Howitt G, Rowlands DJ. Propranolol as ocularhypotensive agent. Br J Ophthalmol 1967; 51: 222-6.
62. Bucci MG, Missiroli A, Pecori GJ, Virno M. [The localadministration of propranolo in the therapy of glaucoma]. Boll Ocul 1968; 47: 51-60.
63. Katz IM, Hubbard WA, Getson AJ, Gould AL. Intraocularpressure decrease in normal volunteers following timololophthalmic solution. Invest Ophthalmol 1976; 15: 489-92.
64. Zimmerman TJ, Kaufman HE. Timolol, dose response andduration of action. Arch Ophthalmol 1977; 95: 605-7.
65. Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN. Adverse respiratory and cardiovascular events attributedto timolol ophthalmic solution, 1987-1985. Am J Ophthalmol 1986; 102: 606-11.
66. Yablonski ME, Zimmerman TJ, Waltman SR, Becker B. Afluorophotometric study of the effect of topical timolol onaqueous humor dynamics. Exp Eye Res 1978; 27: 135-42.
67. Coakes RL, Brubaker RF. The mechanism of timolol inlowering intraocular pressure. In the normal eye. Arch Ophthalmol 1978; 96: 2045-8.
68. Larsson L-I, Rettig ES, Sheridan PT, Brubaker RF. Aqueoushumor dynamics in low-tension glaucoma. Am J Ophthalmol 1993; 116: 590-3.
69. Larsson L-I, Rettig ES, Brubaker RF. Aqueous flow in openangleglaucoma. Arch Ophthalmol 1995; 113: 283-6.
70. Larsson L-I. Aqueous humor flow in normal human eyestreated with brimonidine and timolol, alone and incombination. Arch Ophthalmol 2001; 119: 492-5.
71. Toris CB, Zhan G-L, Yablonski ME, Camras CB. Effects onaqueous flow of dorzolamide combined with either timolol oracetazolamide. J Glaucoma 2004; 13: 210-5.
72. Wayman L, Larsson L-I, Maus T, Alm A, Brubaker RF. Comparison of dorzolamide and timolol as suppressors ofaqueous humor flow in humans. Arch Ophthalmol 1997; 115: 1368-71.
73. Schenker HI, Yablonski ME, Podos SM, Linder L. Fluorophotometric study of epinephrine and timolol in humansubjects. Arch Ophthalmol 1981; 99: 1212-6.
74. Brubaker RF. The flow of aqueous humor in the human eye. Trans Am Ophthalmol Soc 1982; 80: 391-474.
75. Gaul GR, Will NJ, Brubaker RF. Comparison of anoncardioselective beta-adrenoceptor blocker and acardioselective blocker in reducing aqueous flow in humans. Arch Ophthalmol 1989; 107: 1308-11.
76. Reiss GR, Brubaker RF. The mechanism of betaxolol, a newocular hypotensive agent. Ophthalmology 1983; 90: 1369-72.
77. Coulangeon LM, Sole M, Menerath JM, Sole P. Aqueoushumor flow measured by fluorophotometry. A comparativestudy of the effect of various beta-blocker eyedrops inpatients with ocular hypertension. Ophtalmologie 1990; 4: 156-61.
78. Yablonski ME, Novack GD, Burke PJ, Cook DJ, Harmon G. The effect of levobunolol on aqueous humor dynamics. Exp Eye Res 1987; 44: 49-54.
79. Topper JE, Brubaker RF. Effects of timolol, epinephrine, andacetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci 1985; 26: 1315-9.
80. McCannel CA, Heinrich SR, Brubaker RF. Acetazolamide butnot timolol lowers aqueous humor flow in sleeping humans. Graefes Arch Clin Exp Ophthalmol 1992; 230: 518-20.
81. Bartels SP, Roth HO, Jumblatt MM, Neufeld AH. Pharmacological effects of topical timolol in the rabbit eye. Invest Ophthalmol Vis Sci 1980; 19: 1189-97.
82. Brubaker RF, Ingram CJ, Schoff EO, Nau CB. Comparison ofthe efficacy of betaxolol-brinzolamide and timololdorzolamideas suppressors of aqueous humor flow inhuman subjects. Ophthalmology 2000; 107: 283-7.
83. Wayman LL, Larsson L-I, Maus TL, Brubaker RF. Additiveeffect of dorzolamide on aqueous humor flow in patientsreceiving long-term treatment with timolol. Arch Ophthalmol 1998; 116: 1438-40.
84. Dailey BA, Brubaker RF, Bourne WM. The effects of timololmaleate and acetazolamide on the rate of aqueous formationin normal human subjects. Am J Ophthalmol 1982; 93: 232-7.
85. Darier A. De l'extrait de capsule surrénales en thérapeutiqueoculaire. La Clin Ophthalmol 1900; 6: 141-3.
86. Kacere RD, Dolan JW, Brubaker RF. Intravenousepinephrine stimulates aqueous formation in the human eye. Invest Ophthalmol Vis Sci 1992; 33: 2861-5.
87. Lee DA, Brubaker RF, Nagataki S. Acute effect ofthymoxamine on aqueous humor formation in theepinephrine-treated normal eye as measured byfluorophotometry. Invest Ophthalmol Vis Sci 1983; 24: 165-8.
88. Higgins RG, Brubaker RF. Acute effect of epinephrine onaqueous humor formation in the timolol-treated normal eyeas measured by fluorophotometry. Invest Ophthalmol Vis Sci 1980; 19: 420-3.
89. Kronfeld PC. Society Proceedings, Glaucoma Research Conference. Am J Ophthalmol 1963; 55: 821-32.
90. Galin MA, Baras I, Glenn J. L-epinephrine and intraocularpressure. Invest Ophthalmol 1966; 5: 120-4.
91. Mori M, Araie M, Sakurai M, Oshika T. Effects of pilocarpineand tropicamide on blood-aqueous barrier permeability inman. Invest Ophthalmol Vis Sci 1992; 33: 416-23.
92. Schneider TL, Brubaker RF. Effect of chronic epinephrine onaqueous humor flow during the day and during sleep innormal healthy subjects. Invest Ophthalmol Vis Sci 1991; 32: 2507-10.
93. Nagataki S, Brubaker RF. Early effect of epinephrine onaqueous formation in the normal human eye. Ophthalmology 1981; 88: 278-82.
94. Garner LL, Johnstone WW, Ballintine EJ, Carroll ME. Effectof 2% levo-rotary epinephrine on the intraocular pressure ofthe glaucomatous eye. AMA Arch Ophthalmol 1959; 62: 230-8.
95. Weekers R, Prijot E, Gustin J. Mesure de la résistance àl'écoulement de l'humeur aqueuse au moyen du tonemètreélectronique. 6e partie: Mode d'action de l'adrénaline dans leglaucome chronique. Ophthalmologica 1954; 128: 213-7.
96. Nagataki S. Effects of adrenergic drugs on aqueous humordynamics in man. J Jpn Ophthalmol Soc 1977; 81: 1795-800.
97. Araie M, Takase M. Effects of various drugs on aqueoushumor dynamics in man. Jpn J Ophthalmol 1981; 25: 91-111.
98. Ballintine EJ, Garner LL. Improvement of the coefficient ofoutflow in glaucomatous eyes. Arch Ophthalmol 1961; 66: 314-7.
99. Becker B, Pettit TH, Gay AJ. Topical epinephrine therapy ofopen-angle glaucoma. Arch Ophthalmol 1961; 66: 219-25.
100. Becker B, Morton WR. Topical epinephrine in glaucomasuspects. Am J Ophthalmol 1966; 62: 272-7.
101. Weekers R, Prijot E, Gustin J. Recent advances and futureprospects in the medical treatment of ocular hypertension. Br J Ophthalmol 1954; 38: 742-6.
102. Kerr CR, Hass I, Drance SM, Walters MB, Schulzer M. Cardiovascular effects of epinephrine and dipivalylepinephrine applied topically to the eye in patients withglaucoma. Br J Ophthalmol 1982; 66: 109-14.
103. Czechowicz-Janicka K, Kaminska E, Staszkiewicz J. [Use of0.1% dipivefrine chloride for treatment of patients with openangle glaucoma]. Klin Oczna 1995; 97: 248-51.
104. Koskela T, Brubaker RF. Apraclonidine and timolol. Combined effects in previously untreated normal subjects. Arch Ophthalmol 1991; 109: 804-6.
105. Gharagozloo NZ, Relf SJ, Brubaker RF. Aqueous flow isreduced by the alpha-adrenergic agonist, apraclonidinehydrochloride (ALO 2145). Ophthalmology 1988; 95: 1217-20.
106. Toris CB, Camras CB, Yablonski ME. Acute versus chroniceffects of brimonidine on aqueous humor dynamics in ocularhypertensive patients. Am J Ophthalmol 1999; 128: 8-14.
107. Maus TL, Nau C, Brubaker RF. Comparison of the earlyeffects of brimonidine and apraclonidine as topical ocularhypotensive agents. Arch Ophthalmol 1999; 117: 586-91.
108. Schadlu R, Maus TL, Nau CB, Brubaker RF. Comparison ofthe efficacy of apraclonidine and brimonidine as aqueoussuppressants in humans. Arch Ophthalmol 1998; 116: 1441-4.
109. Tsukamoto H, Larsson L-I. Aqueous humor flow in normalhuman eyes treated with brimonidine and dorzolamide, aloneand in combination. Arch Ophthalmol 2004; 122: 190-3.
110. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects ofbrimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995; 113: 1514-7.
111. Reitsamer HA, Posey M, Kiel JW. Effects of a topical ]]2adrenergic agonist on ciliary blood flow and aqueousproduction in rabbits. Exp Eye Res 2006; 82: 405-15.
112. Kubo C, Suzuki R. Involvement of prejunctional alpha 2-adrenoceptor in bovine ciliary muscle movement. J Ocul Pharmacol 1992; 8: 225-31.
113. Camras CB, Podos SM. In: The ocular effects ofprostaglandins and other eicosanoids. Bito LZ, Stjernschantz J, Eds. New York, USA: Alan R. Liss, Inc 1989; Vol. 312: pp.459-75.
114. Toris CB, Gabelt BT, Kaufman PL. Update on themechanism of action of topical prostaglandins for intraocularpressure reduction. Surv Ophthalmol 2008; 53: S107-S120.
115. Sponsel WE, Paris G, Trigo Y, et al. Latanoprost andbrimonidine: therapeutic and physiologic assessment beforeand after oral nonsteroidal anti-inflammatory therapy. Am JOphthalmol 2002; 133: 11-8.
116. Burke J, Kharlamb A, Shan T, et al. In: The imidazolinereceptor: pharmacology, functions, ligands, and relevance tobiology and medicine. Reis DJ, Bousquet P, Parini A, Eds. New York: The New York Academy of Sciences 1995; Vol.763 Pt 1: pp. 78-95.
117. Woodward DF, Krauss AHP, Chen J, et al. Pharmacologicalcharacterization of a novel antiglaucoma agent, bimatoprost(AGN 192024). J Pharmacol Exp Ther 2003; 305: 772-85.
118. Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacologicalcharacteristics of AFP-168 (tafluprost), a new prostanoid FPreceptor agonist, as an ocular hypotensive drug. Exp Eye Res 2004; 78: 767-76.
119. Sagara T, Gaton DD, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN. Topical prostaglandin F 2222treatment reducescollagen types I, III, and IV in the monkey uveoscleral outflowpathway. Arch Ophthalmol 1999; 117: 794-801.
120. Weinreb RN, Kashiwagi K, Kashiwagi F, Tsukahara S, Lindsey JD. Prostaglandins increase matrixmetalloproteinase release from human ciliary smooth musclecells. Invest Ophthalmol Vis Sci 1997; 38: 2772-80.
121. Ocklind A. Effect of latanoprost on the extracellular matrix ofthe ciliary muscle. A study on cultured cells and tissuesections. Exp Eye Res 1998; 67: 179-91.
122. Lütjen-Drecoll E, Tamm E. Morphological study of theanterior segment of cynomolgus monkey eyes followingtreatment with prostaglandin F222. Exp Eye Res 1988; 47: 761-9.
123. Tamm E, Rittig M, Lütjen-Drecoll E. Elektronenmikroskopischeund immunohistochemische untersuchungenzur augendrucksenkenden wirkung von prostaglandin F 2222 [Electron microscopy and immunohistochemical studies ofthe intraocular pressure lowering effect of prostaglandin F222]. Fortschr Ophthalmol 1990; 87: 623-9.
124. Poyer JF, Millar C, Kaufman PL. Prostaglandin F 2222effects onisolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci 1995; 36: 2461-5.
125. Van Alphen GWHM, Wilhelm PB, Elsenfeld PW. The effect ofprostaglandins on the isolated internal muscles of themammalian eye, including man. Doc Ophthalmol 1977; 42: 397-415.
126. Lim KS, Nau CB, O'Byrne MM, et al. Mechanism of action ofbimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology 2008; 115: 790-5.
127. Toris CB, Zhan G, Camras CB. Increase in outflow facilitywith unoprostone treatment in ocular hypertensive patients. Arch Ophthalmol 2004; 122: 1782-7.
128. Wan Z, Woodward DF, Cornell CL, et al. Bimatoprost, prostamide activity, and conventional drainage. Invest Ophthalmol Vis Sci 2007; 48: 4107-15.
129. Bahler CK, Howell KG, Hann CR, Fautsch MP, Johnson DH. Prostaglandins increase trabecular meshwork outflow facilityin cultured human anterior segments. Am J Ophthalmol 2008; 145: 114-9.
130. Crowston JG, Lindsey JD, Aihara M, Weinreb RN. Effect oflatanoprost on intraocular pressure in mice lacking theprostaglandin FP receptor. Invest Ophthalmol Vis Sci 2004; 45: 3555-9.
131. Ota T, Aihara M, Narumiya S, Araie M. The effects ofprostaglandin analogues on IOP in prostanoid FP-receptordeficientmice. Invest Ophthalmol Vis Sci 2005; 46: 4159-63.
132. Crowston JG, Lindsey JD, Morris CA, Wheeler L, Medeiros FA, Weinreb RN. Effect of bimatoprost on intraocularpressure in prostaglandin FP receptor knockout mice. Invest Ophthalmol Vis Sci 2005; 46: 4571-7.
133. Ota T, Aihara M, Saeki T, Narumiya S, Araie M. The IOPloweringeffects and mechanism of action of tafluprost inprostanoid receptor-deficient mice. Br J Ophthalmol 2007; 91: 673-6.
134. Ota T, Aihara M, Saeki T, Narumiya S, Araie M. The effectsof prostaglandin analogues on prostanoid EP1, EP2, andEP3 receptor-deficient mice. Invest Ophthalmol Vis Sci 2006; 47: 3395-9.
135. Crowston JG, Aihara M, Lindsey JD, Weinreb RN. Effect oflatanoprost on outflow facility in the mouse. Invest Ophthalmol Vis Sci 2004; 45: 2240-5.
136. Bill A, Wålinder P-E. The effects of pilocarpine on thedynamics of aqueous humor in a primate (Macaca irus). Invest Ophthalmol 1966; 5: 170-5.
137. Kaufman PL, Gabelt BT. In: Textbook of ocularpharmacology; Zimmerman TJ, Kooner KS, Sharir M, Fechtner RD, Eds. Philadelphia: Lippincott-Raven 1997; pp.221-38.
138. Lütjen-Drecoll E, Wiendl H, Kaufman PL. Acute and chronicstructural effects of pilocarpine on monkey outflow tissues. Trans Am Ophthalmol Soc 1998; 96: 171-91.
139. Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL. Effects of prostaglandins on the aqueous humor outflowpathways. Surv Ophthalmol 2002; 47: S53-S64.
140. Bill A. Effects of atropine and pilocarpine on aqueous humourdynamics in cynomolgus monkeys (Macaca irus). Exp Eye Res 1967; 6: 120-5.
141. Crawford KS, Kaufman PL. Pilocarpine antagonizesprostaglandin F222-induced ocular hypotension in monkeys. Evidence for enhancement of uveoscleral outflow byprostaglandin F222. Arch Ophthalmol 1987; 105: 1112-6.
142. Camras CB, Wang R-F, Podos SM. Effect of pilocarpineapplied before or after prostaglandin F 2222on IOP inglaucomatous monkey eyes. Invest Ophthalmol Vis Sci 1990; 31: 150.
143. Villumsen J, Alm A. Effect of the prostaglandin F 2222analoguePh XA41 in eyes treated with pilocarpine and timolol. Invest Ophthalmol Vis Sci 1992; 33: 1248.
144. Friström B, Nilsson SEG. Interaction of Ph XA41, a newprostaglandin analogue, with pilocarpine. A study on patientswith elevated intraocular pressure. Arch Ophthalmol 1993; 111: 662-5.
145. Kent AR, Vroman DT, Thomas TJ, Herbert RL, Crosson CE. Interaction of pilocarpine with latanoprost in patients withglaucoma and ocular hypertension. J Glaucoma 1999; 8: 257-62.
146. Shin DH, McCracken MS, Bendel RE, et al. The additiveeffect of latanoprost to maximum-tolerated medications withlow-dose, high-dose and no pilocarpine therapy. Ophthalmology 1999; 106: 386-90.
147. Patelska B, Greenfield DS, Liebmann JM, Wand M, Kushnick H, Ritch R. Latanoprost for uncontrolled glaucoma in acompassionate case protocol. Am J Ophthalmol 1997; 124: 279-86.
148. Lindén C, Alm A. Physostigmine increases aqueous humorproduction in human eyes. Curr Eye Res 1997; 16: 1166-70.
149. Toris CB, Zhan G-L, Zhao J, Camras CB, Yablonski ME. Potential mechanism for the additivity of pilocarpine andlatanoprost. Am J Ophthalmol 2001; 131: 722-8.
150. Galin MA, Aizawa F, McLean JM. Urea as an osmotic ocularhypotensive agent in glaucoma. A M A Arch Ophthalmol 1959; 62: 347-52.
151. Krupin T, Podos SM, Becker B. Effect of optic nervetransection on osmotic alterations of intraocular pressure. Am J Ophthalmol 1970; 70: 214-20.
152. Podos SM, Krupin T, Becker B. Effect of small-dosehyperosmotic injections on intraocular pressure of smallanimals and man when optic nerves are transected andintact. Am J Ophthalmol 1971; 71: 898-903.
153. Bito LZ. A new approach to the medical management ofglaucoma, from the bench to the clinic, and beyond: theProctor Lecture. Invest Ophthalmol Vis Sci 2001; 42: 1126-33.
154. Stern FA, Bito LZ. Comparison of the hypotensive and otherocular effects of prostaglandins E2 and F 2222on cat and rhesusmonkey eyes. Invest Ophthalmol Vis Sci 1982; 22: 588-98.
155. Bito LZ, Draga A, Blanco J, Camras CB. Long-termmaintenance of reduced intraocular pressure by daily ortwice daily topical application of prostaglandins to cat orrhesus monkey eyes. Invest Ophthalmol Vis Sci 1983; 24: 312-9.
156. Bito LZ. Comparison of the ocular hypotensive efficacy ofeicosanoids and related compounds. Exp Eye Res 1984; 38: 181-94.
157. Nilsson SFE, Drecoll E, Lütjen-Drecoll E, et al. Theprostanoid EP2 receptor agonist butaprost increasesuveoscleral outflow in the cynomolgus monkey. Invest Ophthalmol Vis Sci 2006; 47: 4042-9.
158. 4 receptor stimulationproduces ocular hypotension by a mechanism that does notappear to involve uveoscleral outflow. Invest Ophthalmol Vis Sci 2009; 50: 3320-8.
159. Martin XD, Malina HZ, Brennan MC, Hendrickson PH, Lichter PR. The ciliary body--the third organ found to synthesizeindoleamines in humans. Eur J Ophthalmol 1992; 2: 67-72.
160. Tobin AB, Unger W, Osborne NN. Evidence for the presenceof serotonergic nerves and receptors in the iris-ciliary bodycomplex of the rabbit. J Neurosci 1988; 8: 3713-21.
161. 3H]5-hydroxytryptamine binding to irisciliarybody tissue of the rabbit. Invest Ophthalmol Vis Sci 1995; 36: 2238-45.
162. 7)autoreceptors. Exp Eye Res 2001; 73: 59-67.
163. Harris LC, Awe SO, Opere CA, Le Day AM, Ohia SE, Sharif NA. Pharmacology of serotonin receptors modulatingelectrically-induced [3H]-norepinephrine release from isolatedmammalian iris-ciliary bodies. J Ocul Pharmacol Ther 2002; 18: 339-48.
164. 2A)receptors: role in IOP reduction. Invest Ophthalmol Vis Sci 2006; 47: 4001-10.
165. 3 receptors in the bovine ciliarymuscle. Eur J Pharmacol 2003; 464: 69-74.
166. Sharif NA, Senchyna M. Serotonin receptor subtype mRNAexpression in human ocular tissues, determined by RT-PCR. Mol Vis 2006; 12: 1040-7.
167. 2) receptor-mediated signal transduction in human ciliarymuscle cells: role in ocular hypotension. J Ocul Pharmacol Ther 2006; 22: 389-401.
168. 2 receptor-mediated phosphoinositide hydrolysis inbovine ciliary epithelium. J Ocul Pharmacol Ther 2003; 19: 55-62.
169. Martin XD, Brennan MC, Lichter PR. Serotonin in humanaqueous humor. Ophthalmology 1988; 95: 1221-6.
170. Veglio F, De Sanctis U, Schiavone D, et al. Evaluation ofserotonin levels in human aqueous humor. Ophthalmologica 1998; 212: 160-3.
171. Gabelt BT, Okka M, Dean TR, Kaufman PL. Aqueous humordynamics in monkeys after topical R-DOI. Invest Ophthalmol Vis Sci 2005; 46: 4691-6.
172. 2 receptor ligands in conscious ocularhypertensive cynomolgus monkeys. J Pharmacol Exp Ther 2003; 306: 301-9.
173. 2 receptor agonist with ocularhypotensive activity. J Med Chem 2006; 49: 318-28.
174. Prünte C, Nuttli I, Markstein R, Kohler C. Effects of dopamineD-1 and D-2 receptors on intraocular pressure in consciousrabbits. J Neural Transm 1997; 104: 111-23.
175. Chu E, Socci R, Chu T-C. PD128,907 induces ocularhypotension in rabbits: involvement of D2/D3 dopaminereceptors and brain natriuretic peptide. J Ocul Pharmacol Ther 2004; 20: 15-23.
176. Chu E, Chu T-C, Potter DE. Mechanisms and sites of ocularaction of 7-hydroxy-2-dipropylaminotetralin: a dopamine3receptor agonist. J Pharmacol Exp Ther 2000; 293: 710-6.
177. Reitsamer HA, Kiel JW. Effects of dopamine on ciliary bloodflow, aqueous production, and intraocular pressure in rabbits. Invest Ophthalmol Vis Sci 2002; 43: 2697-703.
178. Mancino R, Cerulli L, Ricci A, Amenta F. Directdemonstration of dopamine D1-like receptor sites in the ciliarybody of the rabbit eye by light microscope autoradiography. Naunyn Schmiedebergs Arch Pharmacol 1992; 346: 644-8.
179. Piltz JR, Stone RA, Boike S, et al. Fenoldopam, a selectivedopamine-1 receptor agonist, raises intraocular pressure inmales with normal intraocular pressure. J Ocul Pharmacol Ther 1998; 14: 203-16.
180. Virno M, Gazzaniga A, Taverniti L, Pecori GJ, De Gregorio F. Dopamine, dopaminergic drugs and ocular hypertension. Int Ophthalmol 1992; 16: 349-53.
181. Cavallotti C, Pescosolido N, Pescosolido V, Iannetti G. Determination of dopamine D1 receptors in the human uveoscleral tissue by light microscope autoradiography. Int Ophthalmol 1999; 23: 171-9.
182. Grondin R, Goulet M, Di Paolo T, Bédard PJ. Cabergoline, along-acting dopamine D2-like receptor agonist, produces asustained antiparkinsonian effect with transient dyskinesiasin parkinsonian drug-naive primates. Brain Res 1996; 735: 298-306.
183. Nardone R, Ausserer H, Bratti A, et al. Cabergoline reversescortical hyperexcitability in patients with restless legssyndrome. Acta Neurol Scand 2006; 114: 244-9.
184. Potter DE, Ogidigben MJ, Chu T-C. Lisuride acts at multiplesites to induce ocular hypotension and mydriasis. Pharmacology 1998; 57: 249-60.
185. Mekki QA, Hassan SM, Turner P. Bromocriptine lowersintraocular pressure without affecting blood pressure. Lancet 1983; 1: 1250-1.
186. Sharif NA, McLaughlin MA, Kelly CR, et al. Cabergoline:Pharmacology, ocular hypotensive studies in multiplespecies, and aqueous humor dynamic modulation in theCynomolgus monkey eyes. Exp Eye Res 2008; 88: 386-97.
187. Sharif NA, McLaughlin MA, Kelly CR, et al. Cabergoline:Pharmacology, ocular hypotensive studies in multiplespecies, and aqueous humor dynamic modulation in theCynomolgus monkey eyes. Exp Eye Res 2008; 88: 386-97.
188. Ramirez M, Davidson EA, Luttenauer L, et al. The reninangiotensinsystem in the rabbit eye. J Ocul Pharmacol Ther 1996; 12: 299-312.
189. Savaskan E, Löffler KU, Meier F, Müller-Spahn F, Flammer J, Meyer P. Immunohistochemical localization of angiotensinconvertingenzyme, angiotensin II and AT1 receptor inhuman ocular tissues. Ophthalmic Res 2004; 36: 312-20.
190. 1 receptor antagonist, onintraocular pressure in glaucomatous monkey eyes. Exp Eye Res 2005; 80: 629-32.
191. 1 receptor antagonist, on intraocularpressure and aqueous humor dynamics in rabbits. Curr Eye Res 2001; 23: 133-8.
192. Inoue T, Yokoyoma T, Koike H. The effect of angiotensin IIon uveoscleral outflow in rabbits. Curr Eye Res 2001; 23: 139-43.
193. Tian B, Geiger B, Epstein DL, Kaufman PL. Cytoskeletalinvolvement in the regulation of aqueous humor outflow. Invest Ophthalmol Vis Sci 2000; 41: 619-23.
194. Ethier CR, Read AT, Chan DW-H. Effects of latrunculin-B onoutflow facility and trabecular meshwork structure in humaneyes. Invest Ophthalmol Vis Sci 2006; 47: 1991-8.
195. Sabanay I, Tian B, Gabelt BT, Geiger B, Kaufman PL. Latrunculin B effects on trabecular meshwork and cornealendothelial morphology in monkeys. Exp Eye Res 2006; 82: 236-46.
196. Peterson JA, Tian B, Bershadsky AD, et al. Latrunculin-Aincreases outflow facility in the monkey. Invest Ophthalmol Vis Sci 1999; 40: 931-41.
197. Peterson JA, Tian B, McLaren JW, Hubbard WC, Geiger B, Kaufman PL. Latrunculins' effects on intraocular pressure, aqueous humor flow, and corneal endothelium. Invest Ophthalmol Vis Sci 2000; 41: 1749-58.
198. Okka M, Tian B, Kaufman PL. Effects of latrunculin B onoutflow facility, intraocular pressure, corneal thickness, andmiotic and accommodative responses to pilocarpine inmonkeys. Trans Am Ophthalmol Soc 2004; 102: 251-7.
199. Wiederholt M, Thieme H, Stumpff F. The regulation oftrabecular meshwork and ciliary muscle contractility. Prog Retin Eye Res 2000; 19: 271-95.
200. Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization ofsmooth muscle mediated by a Rho-associated protein kinasein hypertension. Nature 1997; 389: 990-4.
201. Rao PV, Deng P-F, Kumar J, Epstein DL. Modulation ofaqueous humor outflow facility by the Rho kinase-specificinhibitor Y-27632. Invest Ophthalmol Vis Sci 2001; 42: 1029-37.
202. Rosenthal R, Choritz L, Schlott S, et al. Effects of ML-7 andY-27632 on carbachol-and endothelin-1-induced contractionof bovine trabecular meshwork. Exp Eye Res 2005; 80: 837-45.
203. Honjo M, Tanihara H, Inatani M, et al. Effects of rhoassociatedprotein kinase inhibitor Y-27632 on intraocularpressure and outflow facility. Invest Ophthalmol Vis Sci 2001; 42: 137-44.
204. Waki M, Yoshida Y, Oka T, Azuma M. Reduction ofintraocular pressure by topical administration of an inhibitorof the Rho-associated protein kinase. Curr Eye Res 2001; 22: 470-4.
205. McLaughlin MA, Toris CB, Brooks DE, et al. Effects of rhokinase inhibitors on intraocular pressure (IOP) and aqueoushumor dynamics in rabbits and monkeys. Invest Ophthalmol Vis Sci 2004; 45: 3534.
206. Lauber JK, Frankelson EN, Boyd TAS. Influence of Diamox(acetazolamide) on aqueous flow. Can J Ophthalmol 1972; 7: 341-8.
207. Ingram CJ, Brubaker RF. Effect of brinzolamide anddorzolamide on aqueous humor flow in human eyes. Am JOphthalmol 1999; 128: 292-6.
208. Maus TL, Larsson L-I, McLaren JW, Brubaker RF. Comparison of dorzolamide and acetazolamide assuppressors of aqueous humor flow in humans. Arch Ophthalmol 1997; 115: 45-9.
209. Christiansen GA, Nau CB, McLaren JW, Johnson DH. Mechanism of ocular hypotensive action of bimatoprost(Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology 2004; 111: 1658-62.
210. Toris CB, Zhan G, Fan S, et al. Effects of travoprost onaqueous humor dynamics in patients with elevatedintraocular pressure. J Glaucoma 2007; 16: 189-95.
211. Gaasterland D, Kupfer C, Ross K. Studies of aqueous humordynamics in man. IV. Effects of pilocarpine uponmeasurements in young normal volunteers. Invest Ophthalmol 1975; 14: 848-53.
212. Gaul GR, Brubaker RF. Measurement of aqueous flow inrabbits with corneal and vitreous depots of fluorescent dye. Invest Ophthalmol Vis Sci 1986; 27: 1331-5.
213. Sharif NA, McLaughlin MA, Kelly CR, et al. Cabergoline:Pharmacology, ocular hypotensive studies in multiplespecies, and aqueous humor dynamic modulation in theCynomolgus monkey eyes. Exp Eye Res 2008; 88: 386-97.
214. Kaufman PL, Erickson KA. Cytochalasin B and D doseoutflowfacility response relationships in the cynomolgusmonkey. Invest Ophthalmol Vis Sci 1982; 23: 646-50.
215. Tian B, Kaufman PL. Effects of the Rho kinase inhibitor Y-27632 and the phosphatase inhibitor calyculin A on outflowfacility in monkeys. Exp Eye Res 2005; 80: 215-25.